PDFs and Translations

This page is a collection of publications that (1) are either not available online or are not readily accessible online and have been uploaded (PDFs Only section); (2) are not in English and have been translated (Translations Only section); or (3) both of the preceding (PDFs and Translations section).

PDFs Only

Not Previously Available Online

Agarwal, V. R., Sasano, H., Takayama, K., Rosenthal, I. M., Walton, R., Simpson, E. R., & Bulun, S. E. (1997). Excessive Levels of Aromatase P450 and its Transcripts in Breast Adipose Tissue of a Girl with Pubertal Macromastia [Abstract P1-393]. In The Endocrine Society - Annual Meeting, Program and Abstracts: 79th Meeting, June 11-14, 1997, Minneapolis, Minnesota. / Proceedings of the 79th Annual Meeting of the Endocrine Society; 1997 June 11-14; Minneapolis, MN, USA. Bethesda, Maryland: Endocrine Society Press. [Google Books] [WorldCat] [PDF]
Anderson, W. A. (1962). Experimental stimulation of breast development in the teen-age female. The Journal of the Medical Society of New Jersey, 59(10), 541–543. [Google Scholar] [PubMed] [PDF]
Aro, J., Ruutu, M., Juusela, H., Hansson, E., & Permi, J. (1993). Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. Annales Chirurgiae et Gynaecologiae, 82(Supplementum 206), 5–8. [Google Scholar] [PubMed] [PDF]
Asscheman, H., Gooren, L. J. G., & Megens, J. (1989). Physical Changes During Hormonal Treatment in Male-to-Female Transsexuals. In Billowitz, A. (Ed.). Proceedings of the XIth Harry Benjamin International Gender Dysphoria Association Symposium, Cleveland, Ohio, September 20–23, 1989 (pp. 14–15). Palo Alto, California: Harry Benjamin International Gender Dysphoria Association. [Google Scholar] [PDF]
Bourg, R. (1950). Activité sécrétrice des glandes mammaires; consécutive a des doses massives de testostérone chez la femme après castration. [Secretory activity of the mammary glands; sequellae of massive testosterone doses in women following castration.] Annales d’Endocrinologie, 11(3), 254–260. [Google Scholar] [PubMed] [PDF]
Capraro, V. J. (1977). Breast Problems in Adolescence. In Moore, T. D., & Levine, H. G. (Eds.). Adolescent Gynecology: Report of the Seventh Ross Roundtable on Critical Approaches to Common Pediatric Problems in Collaboration with the Ambulatory Pediatric Association [, Atlanta, Georgia, March 15, 1976] (pp. 25–31). Columbus, Ohio: Ross Laboratories. [Google Scholar] [Google Books] [WorldCat] [PDF]
Chakmakjian, Z. H., & Zachariah, N. Y. (1987). Bioavailability of progesterone with different modes of administration. The Journal of Reproductive Medicine, 32(6), 443–448. [Google Scholar] [PubMed] [PDF]
Corvol, P., Mahoudeau, J. A., Valcke, J. C., Ménard, J., & Bricaire, H. (1976). Effets sexuels secondaires des spirolactones. Mécanismes possibles de l’action antiandrogène. [Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action]. La Nouvelle Presse Medicale, 5(11), 691–694. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF]
Cowie, A. T. (1951). Recent Studies on the Endocrine Control of the Mammary Development and Milk Secretion. In Centre National de la Recherche Scientifique. Mécanisme Physiologique de la Sécrétion Lactée, Strasbourg, [22-29] Août 1950 (Colloques Internationaux du Centre National de la Recherche Scientifique [Colloq. Int. Cent. Nat. Rech. Sci.], 32) 45–57. [Google Scholar] [PDF]
Dalton, M. E., Guthrie, K. A., & Dalton, K. (1987). A preliminary study into the efficacy of progesterone suppositories as a contraceptive for women with severe premenstrual syndrome. The British Journal of Family Planning, 13(3), 87–89. [Google Scholar] [PDF]
Dewhurst, C., & Spence, J. E. (1977). The XY female. British Journal of Hospital Medicine, 17(5), 498, 501–506. [Google Scholar] [PubMed] [PDF]
Dewhurst, J. (1982). Breast Hypoplasia. In Bruni, V., Gasparri, F., Dewhurst, J., & Rey-Stocker, I. (Eds.). Pediatric and Adolescent Gynaecology [Proceedings of the IVth International Symposium, Florence, October 5-7, 1978] (pp. 205–212). Rome, Italy: Serono Symposia. [Google Scholar] [Google Books] [WorldCat] [PDF]
Dijkman, B., Liberton, N., Sharma, S., Dreijerink, K., Verdaasdonk, R., den Heijer, M., & de Blok, C. (2020). Validation of 3D Pictures with an iPhone X: A Breast Volume Study in Trans Women. World Professional Association for Transgender Health 26th Scientific Symposium, November 6-10, 2020 (abstract no. FRI-1B-T). [Symposium Schedule] [PDF] [Full Abstract Book]
Dix, D., & Cohen, P. (1982). The incidence of breast cancer: analysis of the age dependence. Anticancer Research, 2(1-2), 23–7. [Google Scholar] [PubMed] [PDF]
Dymling, J. F., & Hökfelt, B. (1973). Reduced plasma testosterone following spirolactone in man. Acta Endocrinologica, 73(Suppl 177) [9th Acta Endocrinologica Congress], 53–53 (abstract no. 53). [Google Scholar] [PDF 1] [PDF 2]
Dymling, J. F. (1978). The effect of spirolactone and spironolactone on plasma testosterone in man. In Addison, G. M., Asmussen, N. W., Corvol, P., Kloppernborg, P. W. C., Norman, N., Schroder, R., & Robertson, J. I. C. (Eds.). Aldosterone Antagonists in Clinical Medicine: Proceedings of the Searle Symposium, Nice, April 13–15, 1978 (pp. 297–302). Amsterdam: Excerpta Medica. [Google Scholar] [Google Books] [WorldCat] [PDF 1] [PDF 2]
Foss, G. L. (1956). Abnormalities of form and function of the human breast. Journal of Endocrinology, 14(4 Suppl) [Proceedings of the Society for Endocrinology: Fifty-Fourth Meeting. Symposium on Selected Aspects of the Practice of Hormone Administration in Animals and Man], vi–vii. [Google Scholar] [Google Books] [URL] [PDF]
Freymann, E., Hubl, W., Büchner, M., & Belleée, H. (1977). Eine spezifische, radioimmunologische Bestimmung des Plasmaöstradiols ohne Chromatographie im Zyklus und in der Schwangerschaft und die Bestimmung des freien, nichtproteingebundenen Anteils mittels Dialyse. [A specific radioimmunologi determination of plasma estradiol without chromatography during the cycle and in pregnancy and determination of the free non-protein-bound fraction using dialysis.] Zentralblatt für Gynäkologie, 99(6), 321–329. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF]
Freymann, E., Hubl, W., Büchner, M., & Rohde, W. (1977). Plasma levels of apparent free estradiol during pregnancy. Endokrinologie, 69(2), 269–271. [Google Scholar] [PubMed] [PDF]
Gardner, W. U., Smith, G. M., Allen, E., & Strong, L. C. (1936). Cancer of the mammary glands induced in male mice receiving estrogenic hormone. Archives of Pathology, 21(3), 265–272. [Google Scholar] [PDF]
Geller, J., & Albert, J. D. (1983). Comparison of various hormonal therapies for prostatic carcinoma. Seminars in Oncology, 10(4 Suppl 4), 34–41. [Google Scholar] [PubMed] [PDF]
Geschickter, C. F. (1945). Diseases of the Breast: Diagnosis, Pathology, Treatment, 2nd Edition. Philadelphia: Lippincott. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
Geschickter, C. F. (1945). Endocrine Physiology of the Breast. In Geschickter, C. F. Diseases of the Breast: Diagnosis, Pathology, Treatment, 2nd Edition (pp. 42–81). Philadelphia: Lippincott. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
Hamburger, C., & Benjamin, H. (1969). Endocrine Treatment of Male and Female Transsexualism / Appendix for the Practicing Physician: Suggestions and Guidelines for the Management of Transsexuals. In Green, R., & Money, J. (Eds.). Transsexualism and Sex Reassignment (pp. 291–307). Baltimore: John Hopkins University Press. [Google Scholar] [Google Books] [PDF]
Hammerstein, J. (1979). Cyproterone Acetate. In Jacobs, H. S. (Ed.). Advances in Gynaecological Endocrinology: Proceedings of the Sixth Study Group of the Royal College of Obstetricians and Gynaecologists, 18th and 19th October, 1978 (pp. 367–382). London: The College. [Google Scholar] [Google Books] [PDF]
Hartman, C. G., Geschickter, C. F., & Speert, H. (1941). Effects of continuous estrogen administration in very large dosages. Anatomical Record, 79, 31–31. [Google Scholar] [PDF]
Ibrahim, S. (1996/1998). Pharmakokinetische Untersuchungen mit Östradiolvalerat und Hydroxyprogesteroncaproat in Depotform nach einmaliger Applikation bei 24 postmenopausalen Frauen. [Pharmacokinetic studies with estradiol valerate and hydroxyprogesterone caproate in depot form after a single application in 24 postmenopausal women.] (Doctoral dissertation, Dresden University of Technology.) [Google Scholar] [WorldCat] [Partial PDF]
Jacobsohn, D. (1961). Hormonal Regulation of Mammary Gland Growth. In Kon, S. K., & Cowie, A. T. (Eds.). Milk: The Mammary Gland and Its Secretion, Volume 1 (pp. 127–160). New York: Academic Press. [Google Scholar] [PDF]
Junkmann, K., & Witzel, H. (1957). Chemie und Pharmakologie von Steroidhormon-Estern. [Chemistry and pharmacology of steroid hormone esters.] Zeitschrift für Vitamin-, Hormon-und Fermentforschung, 9(1–2), 97–143. [Google Scholar] [PubMed] [PDF]
Junkmann, K., & Witzel, H. (1957). Chemie und Pharmakologie von Steroidhormon-Estern. 2. TEIL. [Chemistry and pharmacology of steroid hormone esters. Part 2.] Zeitschrift für Vitamin-, Hormon-und Fermentforschung, 9(3–4), 227–257. [Google Scholar] [PubMed] [PDF]
Knuth, U. A., Behre, H., Belkien, L., Bents, H., & Nieschlag, E. (1986). 19-Nortestosterone for male fertility regulation. In Zatuchni, G. I., Goldsmith, A., Spieler, J. M., & Sciarra, J. J. (Eds.). Male Contraception: Advances and Future Prospects: Proceedings of an International Workshop on Male Contraception, Advances and Future Prospects, May 28-31, 1985, Geneva, Switzerland (pp. 320–328). Philadelphia: Harper and Row. [Google Scholar] [Google Books] [WorldCat] [PDF]
Kohli, M., & McClellan, J. (2001). Parenteral Estrogen Therapy in Advanced Prostate Cancer: Retrospective Analysis of Intra-Muscular Estradiol Valerate in “Hormone Refractory” Prostate Disease. In Grunberg, S. M. (Ed.). Proceedings of the American Society of Clinical Oncology [Proc Am Soc Clin Oncol / Proceedings of ASCO], 20 [Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, May 12–15, 2001, San Francisco, California], 164b–164b (abstract no. 2407). Baltimore: Lippincott Williams & Wilkins. [ISSN:1081-0641] [ISBN-10:0-9664495-3-3] [Google Scholar] [WorldCat 1] [WorldCat 2] [WorldCat 3] [PDF]
Kohli, M., Alikhan, M. A., Spencer, H. J., & Carter, G. (2004). Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer. Journal of Clinical Oncology, 22(14 Suppl) [40th Annual Meeting of the American Society of Clinical Oncology: June 5–8, 2004, Ernest N. Morial Convention Center, New Orleans, Louisiana, Annual Meeting Proceedings], 436–436 (abstract no. 4726). [DOI:10.1200/jco.2004.22.90140.4726] [Google Books] [PDF]
Kuhl, H. (1998). Adverse effects of estrogen treatment: natural vs. synthetic estrogens. In Lippert, T. H., Mueck, A. O., & Ginsburg, J. (Eds.). Sex Steroids and the Cardiovascular System: The Proceedings of the 1st Interdisciplinary Workshop, Tuebingen, Germany, October 1996. Parthenon Publishing Group, New York, London (pp. 201–210). London/New York: Parthenon. [Google Scholar] [Google Books] [PDF]
Kuhnz, W., Gansau, C., & Mahler, M. (1993). Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol. Arzneimittelforschung, 43(9), 966–973. [Google Scholar] [PubMed] [PDF]
Lauritzen, C. (1982). Treatment of mammary- and uterus hypoplasia by estrogen-progestagen pseudopregnancy. In Richter, K., Huber, A., Terruhn, V. (Eds.) 1. Europäisches Symposium für Kinder- und Jugendgynäkologie. München 19.-21.3.1981, Band 2 [First European Symposium on Pediatric and Adolescent Gynaecology. München, March 19–21, 1981. Volume 2] (pp. 487–489). Friedrichsdorf/Taunus: Milupa-Aktiengesellschaft, Wissenschaftliche Abteilung. [Google Scholar] [PDF]
Lobo, R. A., & Cassidenti, D. L. (1992). Pharmacokinetics of Oral 17 β-Estradiol. The Journal of Reproductive Medicine, 37(1), 77–84. [Google Scholar] [PubMed] [PDF]
Mikkola, A., Ruutu, M., Aro, J., Rannikko, S., & Salo, J. (1999). The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium. Annales Chirurgiae et Gynaecologiae, 88(1), 18–21. [Google Scholar] [PubMed] [PDF]
Moltz, L., Koch, U., Schwartz, U., Rommler, A., & Hammerstein, J. (1982). Male fertility regulation with cyproterone acetate (CPA). Contraceptive Delivery Systems, 3(3/4) [Retroproductive Health Care International Symposium, October 10-15 1982 Maui, Hawaii, USA, Expanded Abstracts], 298–298 (abstract no. 293). [Google Scholar] [PDF]
Moore, J. W., & Bulbrook, R. D. (1988). The epidemiology and function of sex hormone-binding globulin. Oxford Reviews of Reproductive Biology, 10, 180–236. [Google Scholar] [PubMed] [PDF]
Morris, J. M., & Mahesh, V. B. (1963). Further observations on the syndrome, “testicular feminization”. American Journal of Obstetrics and Gynecology, 87(6), 731–748. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF]
Neumann, F. (1978). The physiological action of progesterone and the pharmacological effects of progestogens – a short review. Postgraduate Medical Journal, 54(Suppl 2), 11–24. [Google Scholar] [PubMed] [PDF]
Norgren, A. (1966–1968). [Mammary Gland Development with Glandectomy and Hormone Administration in Rabbits.] Acta Universitatis Lundensis. Sectio II: Medica, Mathematica, Scientiae Rerum Naturalium. Sweden: University of Lund/C.W.K. Gleerup. [PDF]
Pardridge, W. M. (1988). Selective delivery of sex steroid hormones to tissues by albumin and by sex hormone-binding globulin. Oxford Reviews of Reproductive Biology, 10, 237–292. [Google Scholar] [PubMed] [PDF]
Pentikäinen, P. J., Pentikäinen, L. A., Huffman, D. H., & Azarnoff, D. L. (1974). The effect of spironolactone on plasma levels and excretion of testosterone and oestrogens in the urine in males. (A preliminary report). The Journal of International Medical Research, 2(6), 439–443. [Google Scholar] [PubMed] [PDF]
Petry, R., Mauss, J., Senge, T., & Rausch-Stroomann, J. (1970). Über den Einfluß von Cyproteronacetat, Norethisteronönanthat und Gestonoroncapronat auf die Hypophysen-Gonadenachse beim Mann. [Influence of Cyproterone-acetate, Norethisterone-enanthate and Gestonorone-capronate on the Hypophyseal-Gonadal-Axis in the Male.] In Kracht, J. (Ed.). Endokrinologie der Entwicklung und Reifung, 16. Symposion, Ulm, 26.-28. Februar 1970 (Symposion der Deutschen Gesellschaft für Endokrinologie, Volume 16) (pp. 428–430). Berlin: Springer. [Google Books] [DOI:10.1007/978-3-642-80591-2_118] [WorldCat] [PDF]
Petry, R., Rausch-Stroomann, J.-G., Berthold, K. Mauss, J., Ai, M., Senge, Th., & Vermeulen, A. (1970). Untersuchungen zum Wirkungsmechanismus der Antiandrogene Cyproteron und Cyproteronacetat beim Menschen (Gonadotropin-, Plasma-testosteron- und morphologische Keimdrüsenuntersuchungen). [Investigations on the mechanism of action of the antiandrogens cyproterone and cyproterone acetate in humans (gonadotropin, plasma testosterone, and morphological gonad investigations).] In Schlegel, B. (Ed.). Verhandlungen der Deutschen Gesellschaft für Innere Medizin: Sechsundsiebzigster Kongress Gehalten zu Wiesbaden vom 6. April – 9. April 1970 (Verhandlungen der Deutschen Gesellschaft für Innere Medizin, Volume 76) (pp. 873–876). München: Bergmann. [Google Scholar] [Google Books] [DOI:10.1007/978-3-642-85446-0] [WorldCat] [PDF]
Prior, J. C., Vigna, Y. M., Watson, D., Diewold, P., & Robinow, O. (1986). Spironolactone in the presurgical therapy of male to female transsexuals: Philosophy and experience of the Vancouver Gender Dysphoria Clinic. Journal of Sex Information & Education Council of Canada, 1(1), 1–7. [Google Scholar] [PDF]
Roux, C. (1997). Estrogen therapy in postmenopausal osteoporosis. What we know and what we don’t. Revue du Rhumatisme (English Ed.), 64(6), 402–409. [Google Scholar] [PubMed] [PDF]
Sinkula, A. A. (1978). Methods to Achieve Sustained Drug Delivery. The Chemical Approach. In Robinson, J. R. (Ed.). Sustained and Controlled Release Drug Delivery Systems (pp. 411–555). New York/Basel: Marcel Dekker. [Google Scholar] [Google Books] [PDF]
Spörl, S. (1978/1979). Über den Einfluß von Spironolacton (Aldactone®) auf den Stoffwechsel von Nebennierenrindenhormonen und von Testosteron bei Gesunden mit diätinduziertem Hyperaldosterismus. [On the influence of spironolactone (Aldactone®) on the metabolism of adrenocortical hormones and testosterone in healthy individuals with diet-induced hyperaldosteronism.] (Doctoral dissertation, Freie Universität, Berlin.) [Google Scholar] [Google Books] [WorldCat] [PDF]
Steg, A., & Benoit, G. (1979). Percutaneous 17 β-estradiol in treatment of cancer of prostate. Urology, 14(4), 373–375. [Google Scholar] [PubMed] [DOI:10.1016/0090-4295(79)90083-9] [PDF]
Steg, A., Benoit, G., Limouzin-Lamotte, A., Mahoudeau, J., Caillens, M., & Raichvarg, D. (1979). Cancer de la prostate: effets métaboliques des bêta-estradiol par voie percutanée. [Cancer of the prostate: metabolic effect of percutaneous beta-estradiol. / Prostatic carcinoma: metabolic effect of percutaneous beta-estradiol.] La Nouvelle Presse Medicale, 8(46), 3801–3802. [Google Scholar 1] [Google Scholar 2] [Pascal and Francis] [PubMed] [PDF]
Steg, A., Benoit, G., Limouzin-Lamotte, A., Mahoudeau, J., Caillens, M., & Raichvarg, D. (1980). Cancer de la prostate: Effets métaboliques du bêta-estradiol par voie percutanée. [Cancer of the prostate: metabolic effects of percutaneously administered beta-estradiol.] Revue Médicale de la Suisse Romande, 100(11), 895–897. [Google Scholar 1] [Google Scholar 2] [Pascal and Francis] [PubMed] [PDF]
Steg, A., Benoit, G., Maisonneuve, P., Tallet, F., Nahoul, K., Sultan, Y., Raichwarg, D., & Limouzin-Lamotte, M. A. (1983). Étude comparative du diéthylstilboestrol et du 17 bêta-oestradiol per-cutané dans le traitement du cancer de la prostate. [A comparative study of percutaneous 17 beta-estradiol and diethylstilbestrol in the treatment of prostatic cancer.] Annales d’Urologie, 17(4), 197–202. [Google Scholar] [PDF]
Steg, A., & Benoit, G. (1983). Étude comparative de fortes doses d’oestradiol-17 β administrées par voie per-cutanée et de l’orchidectomie bilatérale dans le traitement du cancer de la prostate. [Prostatic carcinoma. Bilateral orchiectomy versus percutaneous administration of large doses of 17 β-estradiol. A comparative study. / Comparative study of percutaneous administration of large doses of 17β œstradiol and bilateral orchidectomy in prostatic carcinoma.] Annales d’Urologie, 17(5), 286–288. [Google Scholar] [Pascal and Francis] [PDF]
Taylor, A. A., Rollins, D., Snodgrass, W., & Bartter, F. (1976). Effect of spironolactone (S) on adrenal and gonadal steroids in man. Clinical Research, 24(3), A279–A279. [Google Scholar] [PDF]
Tebbens, M., Heijboer, A., T’Sjoen, G., Bisschop, P., & den Heijer, M. (2020). The Influence of Estrone on Estrogenic Effects of Gender Affirming Hormone Treatment. / The Role of Estrone in Gender Affirming Hormone Treatment. World Professional Association for Transgender Health 26th Scientific Symposium, November 6-10, 2020 (abstract no. FRI-6B-T). [PDF]
Wiemeyer, J. C., Fernandez, M., Moguilevsky, J. A., & Sagasta, C. L. (1986). Pharmacokinetic Studies of Estradiol Enantate in Menopausic Women. Arzneimittel-Forschung, 36(11), 1674–1677. [Google Scholar] [PubMed] [PDF]
Wiemeyer, J. C., Fernandez, M., Sagasta, C. L., & Moguilevsky, J. A. (1987). Estudos farmacocinéticos do enantato de estradiol em mulheres na menopausa. [Pharmacokinetic studies of estradiol enantate in menopausic women.] Jornal Brasileiro de Ginecologia, 97(9), 497–501. [Google Scholar] [LILACS] [PDF]
Yan, J., Pan, J., Chang, Y., & Kang, J. (1987). The effect of monthly injectable contraceptive megestrol acetate compound on pituitary-ovarian function. 上海第二医科大学学报(英文版) / Journal of Shanghai Second Medical University / Medical Bulletin of Shanghai Jiaotong University, 1(2), 7–12. [Google Scholar] [CNKI] [PDF]

Paywalled and Not in Shadow Libraries

Ahokas, A., Kaukoranta, J., Wahlbeck, K., & Aito, M. (2001). Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17β-estradiol: a preliminary study. Journal of Clinical Psychiatry, 62(5), 332–336. [DOI:10.4088/jcp.v62n0504] [PDF]
Baker, V. L. (1994). Alternatives to Oral Estrogen Replacement: Transdermal Patches, Percutaneous Gels, Vaginal Creams and Rings, Implants, and Other Methods of Delivery. Obstetrics and Gynecology Clinics of North America, 21(2) [Primary Care of the Mature Woman], 271–297. [DOI:10.1016/S0889-8545(21)00629-X] [PDF]
Burinkul, S., Panyakhamlerd, K., Suwan, A., Tuntiviriyapun, P., & Wainipitapong, S. (2021). Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial. The Journal of Sexual Medicine, 18(7), 1299–1307. [DOI:10.1016/j.jsxm.2021.05.003] [PDF]
Capraro, V. J., & Gallego, M. B. (1975). Breast Disorders. Pediatric Annals, 4(1), 82–96. [DOI:10.3928/0090-4481-19750101-10] [PDF]
Casper, R. F., & Yen, S. S. (1981). Rapid absorption of micronized estradiol-17β following sublingual administration. Obstetrics and Gynecology, 57(1), 62–64. [Google Scholar] [PubMed] [URL] [PDF]
Chantrapanichkul, P., Stevenson, M. O., Suppakitjanusant, P., Goodman, M., & Tangpricha, V. (2021). Serum Hormone Concentrations in Transgender Individuals Receiving Gender-Affirming Hormone Therapy: A Longitudinal Retrospective Cohort Study. Endocrine Practice, 27(1), 27–33. [DOI:10.4158/EP-2020-0414] [PDF]
Chien, Y. W. (1981). Long-acting parenteral drug formulations. Journal of Parenteral Science and Technology / PDA Journal of Pharmaceutical Science and Technology, 35(3), 106–139. [Google Scholar] [URL] [PDF]
Cirrincione, L. R., Winston McPherson, G., Rongitsch, J., Sadilkova, K., Drees, J. C., Krasowski, M. D., Dickerson, J. A., & Greene, D. N. (2021). Sublingual estradiol is associated with higher estrone concentrations than transdermal or injectable preparations in transgender women and gender nonbinary adults. LGBT Health, 8(2), 125–132. [DOI:10.1089/lgbt.2020.0249] [PDF]
Dennerstein, L., Burrows, G. D., Wood, C., & Hyman, G. (1980). Hormones and sexuality: effect of estrogen and progestogen. Obstetrics & Gynecology, 56(3), 316–322. [Google Scholar] [PubMed] [URL] [PDF]
Doll, E., Gunsolus, I., Thorgerson, A., Tangpricha, V., Lamberton, N., & Sarvaideo, J. L. (2022). Pharmacokinetics of sublingual versus oral estradiol in transgender women. Endocrine Practice, 28(3), 237–242. [DOI:10.1016/j.eprac.2021.11.081] [PDF]
Herndon, J. S., Maheshwari, A. K., Nippoldt, T. B., Carlson, S. J., Davidge-Pitts, C. J., & Chang, A. Y. (2023). Comparison of Subcutaneous and Intramuscular Estradiol Regimens as part of Gender-Affirming Hormone Therapy. Endocrine Practice, 29(5), 356–361. [DOI:10.1016/j.eprac.2023.02.006] [URL] [PDF]
Ikemoto, I., Kiyota, H., Abe, K., Hasegawa, T., Ohishi, Y., Aizawa, Y. (2000). ビカルタミドにより惹起された重症肝障害. [Bicalutamide-induced Liver Toxicity in a Patient with Prostate Cancer.] 臨床泌尿器科 [Rinsho Hinyokika], 54(6), 489–491. [DOI:10.11477/mf.1413902997] [PDF]
Langley, R. E., Gilbert, D. C., Duong, T., Clarke, N. W., Nankivell, M., Rosen, S. D., Mangar, S., Macnair, A., Sundaram, S. K., Laniado, M. E., Dixit, S., Madaan, S., Manetta, C., Pope, A., Scrase, C. D., Mckay, S., Muazzam, I. A., Collins, G. N., Worlding, J., Williams, S. T., Paez, E., Robinson, A., McFarlane, J., Deighan, J. V., Marshall, J., Forcat, S., Weiss, M., Kockelbergh, R., Alhasso, A., Kynaston, H., & Parmar, M. (2021). Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. The Lancet, 397(10274), 581–591. [DOI:10.1016/s0140-6736(21)00100-8] [PDF] [Supplementary appendix]
Liang, J. J., Jolly, D., Chan, K. J., & Safer, J. D. (2018). Testosterone levels achieved by medically treated transgender women in a United States endocrinology clinic cohort. Endocrine Practice, 24(2), 135–142. [DOI:10.4158/EP-2017-0116] [PDF]
Lobo, R. A. (1987). Absorption and metabolic effects of different types of estrogens and progestogens. Obstetrics and Gynecology Clinics of North America, 14(1), 143–167. [PubMed] [DOI:10.1016/S0889-8545(21)00577-5] [URL] [PDF]
Meyer, G., Mayer, M., Mondorf, A., Flügel, A. K., Herrmann, E., & Bojunga, J. (2020). Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. European Journal of Endocrinology, 182(2), 149–156. [DOI:10.1530/eje-19-0463] [PDF]
Sang, G. W., Ge, J. L., Liu, X. H., Shao, Q. X., Zhao, X. J., & Mao, S. M. (1987). 不同剂量庚炔诺酮单独或配伍戊酸雌二醇后的药代动力学及药效学. [Pharmacokinetics and pharmacodynamics of different doses of norethisterone enanthate alone and in combination with estradiol valerate.] 中国临床药理学杂志 / Chinese Journal of Clinical Pharmacology, 3(1), 7–18. [Google Scholar] [CNKI] [DOI:10.13699/j.cnki.1001-6821.1987.01.002] [PDF]
Schug, B. S., Donath, F., & Blume, H. H. (2012). Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following IM single dose administration in healthy postmenopausal volunteers. International Journal of Clinical Pharmacology and Therapeutics, 50(2), 100–117. [Google Scholar] [DOI:10.5414/cp201589] [PDF 1] [PDF 2]
Sofer, Y., Yaish, I., Yaron, M., Bach, M. Y., Stern, N., & Greenman, Y. (2020). Differential Endocrine and Metabolic Effects of Testosterone Suppressive Agents in Transgender Women. Endocrine Practice, 26(8), 883–890. [DOI:10.4158/ep-2020-0032] [PDF]
Tangpricha, V., & Safer, J. D. (2020). Transgender Women: Evaluation and Management. UpToDate. [URL] [PDF]

Not Readily Accessible Online

Bässler, R. (1970). The Morphology of Hormone Induced Structural Changes in the Female Breast. In Altmann, H.-W., et al. (Eds.). Current Topics in Pathology: Ergebnisse der Pathology, Volume 53 (pp. 1–89). Heidelberg: Springer Berlin. [DOI:10.1007/978-3-662-30514-0_1] [PDF]
Basson, R., & Prior, J. C. (1998). Hormonal Therapy of Gender Dysphoria: The Male-to-Female Transsexual. In Denny, D. (Ed.). Concepts in Transgender Identity (Garland Gay and Lesbian Studies, Volume 11) (pp. 277–296). New York: Garland Publishing Inc. [Google Scholar] [Google Books] [DOI:10.4324/9780203775134-19] [PDF]
Batheja, P., Thakur, R., & Michniak, B. (2006). Basic Biopharmaceutics of Buccal and Sublingual Absorption. In Touitou, E., & Barry, B. W. (Eds.). Enhancement in Drug Delivery (pp. 175–202). Boca Raton/London/New York: CRC Press. [Google Scholar] [Google Books] [DOI:10.1201/9781420004816-17] [PDF]
Boogers, L., Infirri, S. S., Bouchareb, A., de Blok, C., Liberton, N., van Trotsenburg, P., Dreijerink, K., den Heijer, M., Wiepjes, C., & Hannema, S. (2022). The effect of timing of puberty suppression on breast development in trans girls; a cross-sectional study. Hormone Research in Paediatrics, 95(Suppl 2) [60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE), Rome, Italy, September 15–17, 2022], 390–391 (abstract no. P1-379). [Google Scholar] [DOI:10.1159/000525606] [URL] [PDF 1] [PDF 2]
Boylan, J. F. (2014). Dr. Christine McGinn. In Boylan, J. F. Stuck in the Middle with You: A Memoir of Parenting in Three Genders (pp. 223–233). New York: Broadway Books. [Google Scholar] [Google Books 1] [Google Books 2] [WorldCat] [PDF]
Cheung, A. S., Ooi, O., Davidoff, D., Leemaqz, S. Y., Cundill, P., Silberstein, N., Bretherton, I., Grossmann, M., & Zajac, J. D. (2018). Cyproterone vs spironolactone as anti-androgen therapy for transgender females receiving oestradiol therapy. Clinical Endocrinology, 89(S1) [Abstracts of the Endocrine Society of Australia’s Annual Scientific Meeting 2017], 14–14 (abstract no. 62). [Google Scholar] [DOI:10.1111/cen.13727] [URL 1] [URL 2] [PDF]
Cooper, M. A. (1984). Hormone treatment clinic for transsexuals. Hawaii Medical Journal, 43(5), 142–144. [Google Scholar] [PubMed] [Archive.org] [PDF]
Cox, C. B., Kent, J. C., Owens, R., & Hartmann, P. E. (1994). Mammary morphological and functional changes during pregnancy in women. In Thompson, J. (Ed.). Proceedings of the Twenty-Sixth Annual Conference, Hilton Hotel, Brisbane, 26–28 September, 1994 [The Australian Society for Reproductive Biology Inc., Twenty Sixth Annual Conference, The Hilton Hotel, Brisbane, September 26 - 28 1994, Programme and Miniposters of Papers] (pp. 47–47). Australia: Australian Society for Reproductive Biology. [Google Scholar] [WorldCat] [URL] [PDF]
Deutsch, M. (2014). Medical Transition. In Erickson-Schroth, L. (Ed.). Trans Bodies, Trans Selves: A Resource for the Transgender Community, 1st Edition (pp. 241–264). Oxford: Oxford University Press. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
Edmonds, D. K. (1989). Normal Puberty. In Edmonds, D. K. Dewhurst’s Practical Paediatric and Adolescent Gynaecology, 2nd Edition (pp. 56–62). London: Butterworths. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [URL] [Archive.org] [PDF]
Folley, S. J. (1950). Lactational Physiology. In Bowes, K. (Ed.). Modern Trends in Obstetrics and Gynaecology (pp. 441–453). London: Butterworth. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [PDF]
Folley, S. J. (1952). Lactation. In Parkes, A. S. (Ed.). Marshall’s Physiology of Reproduction, Volume II, 3rd Edition. Longmans, Green and Co.: London. [Google Scholar] [Google Books] [PDF]
Futterweit, W. (1980). Endocrine management of transsexual. Hormonal profiles of serum prolactin, testosterone, and estradiol. New York State Journal of Medicine, 80(8), 1260–1264. [Google Scholar] [PubMed] [Archive.org] [PDF]
Geller J. (1991). Megestrol Acetate Plus Low-Dose Estrogen in the Management of Advanced Prostatic Carcinoma. The Urologic Clinics of North America, 18(1), 83–91. [DOI:10.1016/S0094-0143(21)01395-1] [Archive.org] [PDF]
Goldenberg, S. L., & Bruchovsky, N. (1991). Use of Cyproterone Acetate in Prostate Cancer. The Urologic Clinics of North America, 18(1), 111–122. [DOI:10.1016/S0094-0143(21)01398-7] [Archive.org] [PDF]
Huffman, J., Dewhurst, C. J., & Capraro, V. J. (1981). The Breast and its Disorders in Childhood and Adolescence. In Huffman, J., Dewhurst, J., & Capraro, V. The Gynecology of Childhood and Adolescence, 2nd Edition (pp. 542–559). Philadelphia: Saunders. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
Jacobi, G. H., Tunn, U., & Senge, T. (1982). Clinical experience with cyproterone acetate for palliation of inoperable prostate cancer. In Jacobi, G. H., & Hohenfellner, R. (Eds.). Prostate Cancer (International Perspectives in Urology, Volume 3) (pp. 305–319). Baltimore: Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
Kennealey, G. T., & Furr, B. J. (1991). Use of the Nonsteroidal Anti-androgen Casodex in Advanced Prostatic Carcinoma. The Urologic Clinics of North America, 18(1), 99–110. [DOI:10.1016/S0094-0143(21)01397-5] [URL] [Archive.org] [PDF]
Kloosterboer, H. J., Schoonen, W. G., & Verheul, H. A. (2008). Proliferation of Breast Cells by Steroid Hormones and Their Metabolites. In Pasqualini, J. R. (Ed.). Breast Cancer: Prognosis, Treatment, and Prevention, 2nd Edition (pp. 343–366). New York/London: Informa Healthcare. [Google Scholar] [PDF]
Kuhl, H. (1997). Ideal dose of ethinylestradiol. In Elstein, M. (Ed.). Extragenital Effects of Oral Contraceptives: [4th Congress of the European Society of Contraception, Barcelona, Spain, June 1996] (pp. 27–38). Lancashire/New York: Parthenon. [Google Scholar] [Google Books] [Partial PDF]
Kuhl, H. (1999). Hormonal contraception. In Oettel, M., & Schillinger, E. (Eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen (Handbook of Experimental Pharmacology, Volume 135, Part 2) (pp. 363–407). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-60107-1_18] [PDF]
Kuhl, H. (2005). Gallbladder, liver, pancreas. In Lauritzen, C., & Studd, J. (Eds.). Current Management of the Menopause (pp. 362–372). London/New York: Taylor & Francis. [Google Scholar] [Google Books] [PDF]
Kutten, F., Malet, C., & Leygue, E. (1994). Antiestrogen action of progestogens in human breast cells. In Berg, G., & Hammar, M. (Eds.). The Modern Management of the Menopause: A Perspective for the 21st Century [The Proceedings of the VII International Congress on the Menopause, Stockholm, Sweden 1993] (pp. 419–433). Canforth: Parthenon. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
Laurence, D. J., Monaghan, P., & Gusterson, B. A. (1991). The Development of the Normal Human Breast. Oxford Reviews of Reproductive Biology, 13, 149–174. [Google Scholar] [PubMed] [Archive.org] [PDF]
Nappi, R. E., Sommacal, A., Sances, G., Abbiati, I., Ferdeghini, F., Vercesi, C., Albani, F., & Polatti, F. (2004). Progesterone supplementation on mood and sexual well-being. Gynecological Endocrinology, 18(Suppl 1 [Abstracts of the 11th World Congress of Gynecological Endocrinology, Florence, Italy, February 26-29, 2004]), 133–134 (abstract no. S9). [Google Scholar] [PubMed] [URL] [PDF]
Neyman, A., Fuqua, J. S., & Eugster, E. A. (2017). Bicalutamide as an Androgen Blocker with Secondary Effect of Promoting Feminization in Male to Female (MTF) Transgender Adolescents. Hormone Research in Paediatrics, 88(Suppl 1 [10th Individual Abstracts for International Meeting of Pediatric Endocrinology: Free Communication and Poster Sessions, Abstracts]), 477–477 (abstract no. P3-605). [DOI:10.1159/000481424] [PDF]
Prior, J. C., & Elliott, S. (1998). Hormonal Therapy of Gender Dysphoria: The Female-to-Male Transsexual. In Denny, D. (Ed.). Concepts in Transgender Identity (Garland Gay and Lesbian Studies, Volume 11) (pp. 297–313). New York: Garland Publishing Inc. [Google Scholar] [Google Books] [DOI:10.4324/9780203775134-20] [PDF]
Regan, P. C. (1999). Hormonal correlates and causes of sexual desire: A review. The Canadian Journal of Human Sexuality, 8(1), 1–16. [Google Scholar] [URL] [PDF 1] [PDF 2]
Sahlin, L., & Schoultz, B. V. (1999). Liver Inclusive Protein, Lipid and Carbohydrate Metabolism. In Oettel, M., & Schillinger, E. (Eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen (Handbook of Experimental Pharmacology, Volume 135, Part 2) (pp. 163–178). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-60107-1_8] [PDF]
Sayeed, V. A., & Ashraf, M. (2014). Considerations in Developing Sublingual Tablets—An Overview. Pharmaceutical Technology, 38(11), 34–72. [Google Scholar] [URL] [PDF]
Seal, L. J. (2007). The Practical Management of Hormonal Treatment in Adults with Gender Dysphoria. In Barrett, J. (Ed.). Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management (pp. 157–190). Oxford/New York: Radcliffe Publishing. [Google Scholar] [Google Books] [DOI:10.1201/9781315377605-15] [PDF]
Speert, H. (1948). The Normal and Experimental Development of the Mammary Gland of the Rhesus Monkey, with Some Pathological Correlations. Contributions to Embryology, 32(208), 9–65. Carnegie Institution of Washington. [Google Scholar] [HathiTrust] [PDF]
Styne, D. M. (2019). Physiology and Disorders of Puberty. In Melmed, S., Koenig, R. J., Rosen, C. J., Auchus, R. J., Goldfine, A. B., & Williams, R. H. (Eds.). Williams Textbook of Endocrinology (pp. 1023–1164.e25). Philadelphia: Elsevier. [URL] [DOI:10.1016/B978-0-323-55596-8.00026-7] [PDF]
Wilson, R. A., Brevetti, R. E., & Wilson, T. A. (1963). Specific Procedures for the Elimination of the Menopause. Western Journal of Surgery, Obstetrics, and Gynecology, 71(1), 110–121. [Google Scholar] [PubMed 1] [PubMed 2] [PDF]

Miscellaneous

Angus, L. M., Leemaqz, S., Zajac, J. D., & Cheung, A. S. (2023). A randomised controlled trial of spironolactone versus cyproterone in trans people commencing estradiol. AusPATH 2023 Symposium. [URL] [PDF] [Trans Health Research Blog Post]
Angus, L. M., Leemaqz, S. Y., Zajac, J. D., & Cheung, A. S. (2023). The effect of cyproterone and spironolactone on breast development in transgender women: a randomised controlled trial. ESA/SRB/ENSA 2023 ASM 26-29 November, Brisbane, 54–55 (abstract no. 132). [URL] [PDF] [Full Abstract Book] [Trans Health Research Blog Post]
Angus, L., Mikolajczyk, M., Cheung, A., Zajac, J., Antoszewski, B., & Kasielska-Trojan, A. (2022). Estimation of breast volume in transgender women using 2D photography: validation of the BreastIdea Volume Estimator in men and transgender women. ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme, 127–127 (abstract no. 279). [URL] [PDF] [Full Abstract Book]
Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]), 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
Capraro, V. J., & Dewhurst, C. J. (1975). Breast disorders in childhood and adolescence. Clinical Obstetrics and Gynecology, 18(2), 25–50. [DOI:10.1097/00003081-197506000-00003] [PDF]
Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline [2nd Version]. The Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. [DOI:10.1210/jc.2017-01658] [PDF]
Igo, J., & Visram, H. (2021). Progesterone Therapy Use and Safety in Male to Female Transgender Patients. Canadian Journal of Diabetes, 45(7 Suppl), S39–S39 (abstract no. 109). [DOI:10.1016/j.jcjd.2021.09.119] [URL] [PDF]
Igo, J., & Visram, H. (2021). Testosterone Suppression With Injectable Estrogen Therapy Alone in Male to Female Transgender Patients. Canadian Journal of Diabetes, 45(7 Suppl), S40–S40 (abstract no. 114). [DOI:10.1016/j.jcjd.2021.09.124] [URL] [PDF]
Krishnamurthy, N., Slack, D., Kyweluk, M., Kirkley, J., Trakhtenberg, E., Contreras-Castro, F., & Safer, J. (2023). Not All Transfeminine Individuals on Estradiol Can Reach Both Target Testosterone and Target Estradiol Levels—Time to Revisit Treatment Guidelines? USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions, 94–94 (abstract no. SAT-B2-T4). [Symposium Schedule] [PDF] [Full Abstract Book]
Prior, J. C. (2008–2010). Preventive Powers of Ovulation and Progesterone. Centre for Menstrual Cycle and Ovulation Research (CeMCOR). [Google Scholar] [PDF]
Stege, R., Carlström, K., Collste, L., Eriksson, A., Henriksson, P., & Pousette, A. (1988). Single drug polyestradiol phosphate therapy in prostatic cancer. American Journal of Clinical Oncology, 11(Suppl 2), S101–S103. [DOI:10.1097/00000421-198801102-00024] [PDF]
TransHub. (2020). Hormones - Feminising. ACON. [URL] [PDF]
Vierregger, K., Tetzlaf, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions, 96–96 (abstract no. SAT-B2-T4). [Symposium Schedule] [PDF] [Full Abstract Book]
Warus, J., Rincon, M. G., Salvetti, B., & Olson-Kennedy, J. (2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions, 124–124 (abstract no. SUN-B1-T5). [Symposium Schedule] [PDF] [Full Abstract Book]
Whitelaw, M. J., & Foster, T. N. (1960). Hormonal Influence on Linear and Bone Growth in Children. B. Estrogens, Progestogens and Testosterone. Acta Endocrinologica (Copenhagen), 34(1 Suppl a) / Suppl 51 [First International Congress of Endocrinology, Copenhagen, 1960], 1339–1339 (abstract no. 675). [Google Scholar] [DOI:10.1530/acta.0.XXXIV1329] [PDF] [Cited by Whitelaw et al. (1962) and Whitelaw (1967)]

Translations Only

Choi, Y. H., Park, M. K., Kim, Y. G., Lee, S. M., Son, H. J., Park, H. C., Kim, S. T., Choi, I. S., & Kim, K. K. (2012). 식물추출물 팩의 여성가슴 탄력증진과 크기증대에 관한 연구. [Effects of Tested Pack Containing Plant Extracts on Elasticity and Size of Women’s Breasts.] 생명과학회지 [Journal of Life Science], 22(3), 407–416. [Google Scholar] [KMBASE] [DOI:10.5352/JLS.2012.22.3.407] [PDF] [Translation]
Fauvet, E. (1940). Vergleichende Untersuchungen über die Entwicklung und Funktion der Milchdrüsen. V. Experimentelle Untersuchungen über den Einfluß der Ovarialhormone auf die Milchdrüsen der Ratten. [The development and function of mammary glands. V. The effect of the ovarian hormone on the mammary glands of rats.] Archiv für Gynäkologie, 170(2), 244–257. [Google Scholar 1] [Google Scholar 2] [DOI:10.1007/BF01761510] [Translation]
Göretzlehner, G., Ackermann, W., Angelow, K., Bergmann, G., Bieck, E., Golbs, S., & Kliem, O. (2002). Pharmakokinetik von Estron, Estradiol, FSH, LH und Prolaktin nach intramuskulärer Applikation von 5 mg Estradiolvalerat. [Pharmacokinetics of estradiol valerate in postmenopausal women after intramuscular administration.] Journal für Menopause, 9(2), 46–49. [Google Scholar] [URL] [PDF] [Translation]
Kaiser, R. (1962). Über die Oestrogenausscheidung nach Injektion von Oestradiolestern. [Estrogen excretion after injection of estradiol esters.] In Nowakowski, H. (Ed.). Gewebs-und Neurohormone: Physiologie des Melanophorenhormons [Tissue and Neurohormones: Physiology of the Melanophore Hormone] (pp. 227–232). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-86860-3_24] [Translation]
Kuhl, H. (1990). Ovulationshemmer: Die Bedeutung der Östrogendosis. [Ovulation Preventives: The Significance of the Estrogen Dose. / Ovulation Inhibitors: The Significance of Estrogen Dose.] Geburtshilfe und Frauenheilkunde, 50(12), 910–922. [Google Scholar 1] [Google Scholar 2] [PubMed] [DOI:10.1055/s-2008-1026392] [Translation]
Kuhl, H., & Wiegratz, I. (2021). Pharmakokinetik und Pharmakodynamik der in der Assistierten Reproduktion Verwendeten Gestagene. [Pharmacokinetics and Pharmacodynamics of Progestogens Used in Assisted Reproduction.] Gynäkologische Endokrinologie [Gynecological Endocrinology], 19, 105–117. [Google Scholar] [DOI:10.1007/s10304-020-00372-5] [Translation]
Lauritzen, C. (1975). Erfahrungen mit der Oestrogenbehandlung des Hochwuchses bei jungen Mädchen. [Experiences with estrogen therapy of gigantism in young girls.] Archives of Gynecology and Obstetrics, 219(1), 582–584. [Google Scholar 1] [Google Scholar 2] [PubMed] [DOI:10.1007/BF00669259] [Translation]
Murakami, M., Kawai, K., Higuchi, K., Yanaihara, T., Araki, H., & Nakayama, T. (1988). 思春期女子乳房発育とその内分泌学的背景. [Correlation between breast development and hormone profiles in pubertal girls.] Nihon Sanka Fujinka Gakkai Zasshi [Journal of the Japanese Obstetrical and Gynecological Society], 40(5), 561–567. [Google Scholar] [PubMed] [PDF] [Translation]
Premoli, F., Re, I., Asenjo, G., Maximino, G., & Micheletti, L. (2005). Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE). [Transdermal Scrotal Estrogen Patches (TSEP) in the Treatment of Advanced Prostate Cancer.] Revista Argentina de Urología, 70(4), 231–241. [Google Scholar] [URL] [PDF] [Translation]
Sapin, R., Neamtu, D., Gasser, F., Ohl, J., Grunenberger, F., & Grucker, D. (2000). De la prudence lors de l’utilisation des dosages directs de progestérone. [Caution when using direct progesterone assays.] Immuno-analyse et Biologie Spécialisée, 3(15), 203–204. [DOI:10.1016/S0923-2532(00)80010-1] [Translation]
Tóth, M. (2009). Mioanabolikus Szteroidok és Szelektív Androgénreceptormodulátorok: Hatásmechanizmus és Terápiás Perspektívák. [Myoanabolic Steroids and Selective Androgen Receptor Modulators: Mechanism of Action and Perspectives. Orvosi Hetilap, 150(45), 2051–2059. [DOI:10.1556/oh.2009.28739] [Translation]
Valle Alvarez, D. C. (2011). Efecto de una Dosis de 50 mg de Enantato de Noretisterona y 5 mg de Valerato de Estradiol en los Niveles de Testosterona Total en Hombres Mexicanos Sanos. [Effect of a Dose of 50 mg of Norethisterone Enanthate and 5 mg of Estradiol Valerate on Total Testosterone Levels in Healthy Mexican Men.] (Masters thesis, National Polytechnic Institute of Mexico.) [Google Scholar] [URL] [PDF] [Translation]
Translated French Government Reports on Cyproterone Acetate and Meningioma (2018–2019) (ASNM/CNAM)

PDFs and Translations

Becerra Fernández, A., de Luis Román, D. A., & Piédrola Maroto, G. (1999 October 23). Morbilidad en Pacientes Transexuales con Autotratamiento Hormonal para Cambio de Sexo. [Morbidity in Transsexual Patients with Cross-Gender Hormone Self-Treatment.] Medicina Clínica (Barcelona), 113(13), 484–487. [ISSN:0025-7753] [Google Scholar 1] [Google Scholar 2] [PubMed] [WorldCat] [PDF 1] [PDF 2] [Translation]
Benoit, G. (1985). Que Penser du Traitement Hormonal du Cancer de la Prostate / Hormonothérapie du Cancer de la Prostate. [Thoughts on the Hormonal Treatment of Prostate Cancer / Hormone Therapy of Prostate Cancer.] Gazette Médicale, 92(5), 33–39. [Google Scholar] [PDF] [Translation]
Bruck, H. G., & Müller, G. (1967). Zur Hormontherapie der Hypoplastischen Weiblichen Brust. [On Hormonal Therapy of the Hypoplastic Female Breast.] Ästhetische Medizin [Ästhetische Medizin : Kongreß-Organ der Deutschen Gesellschaft für die Ästhetische Medizin und ihre Grenzgebiete], 16(12), 365–366. [ISSN:0400-6755] [Google Scholar] [PubMed] [WorldCat] [PDF] [Translation]
Cernea, R. (1944). Lokale Hormonbehandlung bei Mammaatrophie und Unterentwicklung. [Local Hormone Treatment in Mammary Atrophy and Underdevelopment.] Medizinische Klinik, 40(11/12), 169–170. [Google Scholar] [PDF] [Translation]
Derra, C. (1981). Hormonprofile unter Östrogen- und Antiandrogentherapie bei Patienten mit Prostatakarzinom: Östradiolundecylat versus Cyproteronacetat. [Hormone Profiles under Estrogen and Antiandrogen Therapy in Patients with Prostate Cancer: Estradiol Undecylate versus Cyproterone Acetate.] (Doctoral dissertation, University of Mainz.) [Google Scholar] [WorldCat] [PDF] [Translation]
Enfedjieff, M. (1974). Erfahrungen mit der Hormonbehandlung des Prostatakarzinoms. [Experiences with hormonal treatment of prostatic carcinoma.] Zeitschrift für Urologie und Nephrologie, 67(3), 717–773. [Google Scholar] [PubMed] [Popline] [PDF] [Translation]
Geppert, G. (1975). Untersuchungen zur Pharmakokinetik von Östradiol-17β, Östradiol-Benzoat, Östradiol-Valerianat und Östradiol-Undezylat bei der Frau: Der Verlauf der Konzentrationen von Östradiol-17β, Östron, LH und FSH im Serum. [Studies on the Pharmacokinetics of Estradiol-17β, Estradiol Benzoate, Estradiol Valerate, and Estradiol Undecylate in Women: The Course of the Relationships Between Estradiol-17β, Estrone, LH, and FSH in Serum.] (Doctoral dissertation, University of Bonn.) [Google Scholar] [WorldCat] [PDF] [Translation]
Ghazli, M., Morsad, F., Salah-Eddine, A., El Karroumi, M., Samouh, N., Matar, N., & El Mansouri, A. (2000). La Puberté Féminine: Résultats d’une Enquête auprès de 2000 Adolescentes Marocaines. [Female Puberty: Results of a Survey of 2000 Moroccan Adolescent Girls.] Maghreb Médical, 20(345), 99–104. [Google Scholar] [WHO] [PDF] [Translation]
Godano, A., Massara, D., Grassi, G., Genovese, M. G., Cavallotti, G. P., & Bocchini, R. (1990). Transessualismo maschile e terapia ormonale: quadri radiologici mammari. [Male transsexualism and hormonal therapy: radiologic pictures of the breast.] Archivio Italiano di Urologia, Nefrologia, Andrologia, 62(1), 107–111. [Google Scholar] [PubMed] [PDF] [Translation]
Göretzlehner, G. & Lauritzen, C. (1992). Hormontherapie bei Gynäkologischen Erkrankungen [Hormone Therapy for Gynecological Diseases]. In Göretzlehner, G. & Lauritzen, C. Praktische Hormontherapie in der Gynäkologie, 1. Auflage [Practical Hormone Therapy in Gynecology, 1st Edition] (pp. 245–299). Berlin/New York: de Gruyter. [DOI:10.1515/9783112417706-007] [Google Books] [PDF] [Translation]
Hamburger, C. (1951). Mode d’administration des hormones stéroïdes et son importance thérapeutique. [Administration of the steroid hormones and its therapeutic significance.] Schweizerische Medizinische Wochenschrift, 81(41), 995–999. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF] [Translation]
Ittrich, G., & Pots, P. (1965). Östrogenbestimmungen in Blut und Urin nach Verabreichung von Östrogenen. [Estrogen determinations in blood and urine after administration of estrogens.] In Kraatz, H. (Ed.). International Symposium der Gynäkologischen Endokrinologie vom 15. bis 18. Mai 1963. / Abhandlungen der Deutschen Akademie der Wissenschaften zu Berlin, Klasse für Medizin, 1965(1), 53–56. [ISSN:0568-4250] [WorldCat 1] [WorldCat 2] [WorldCat 3] [PDF] [Translation]
Jacobi, G. H. (1981). Therapie des Prostatakarzinoms mit Antiandrogenen. [Therapy of Prostate Cancer with Antiandrogens.] In Altwein, J. E., Bartsch, G., & Jacobi, G. H. (Eds.). Antihormone, Bedeutung in der Urologie [Antihormones, Importance in Urology] (Klinische und Experimentelle Urologie, Band 2 [Clinical and Experimental Urology, Volume 2]) (pp. 277–289). München: Zuckschwerdt. [WorldCat] [PDF] [Translation]
Kaiser, R. (1961). Die Östrogenausscheidung im Zyklus und nach Injektion von Ostradiolester: Ein Beitrag zur Therapie mit Depotsöstrogenen. [Estrogen excretion during the cycle and after injection of estradiol esters. A contribution to therapy with depot estrogens.] Geburtshilfe und Frauenheilkunde, 21, 868–873. [Google Scholar] [PubMed] [PDF] [Translation]
Kaiser, R., & Leidenberger, F. (1991). Hormonbehandlung bei Benign Mammaerkrankungen: Mammahypoplasie. [Hormonal Treatment in Benign Breast Diseases: Breast Hypoplasia.] In Kaiser, R., & Leidenberger, F. Hormonbehandlung in der Gynäkologischen Praxis, 7. Auflage [Hormone Treatment in Gynecological Practice, 7th Edition] (pp. 138–138). Stuttgart: Georg Thieme Verlag. [Google Books] [OpenLibrary] [WorldCat] [PDF] [Translation]
Kozlov, G. I., Mel’nichenko, G. A., & Golubeva, I. V. (1985). Случай лактореи у больного мужского пола с транссексуализмом. [Sluchai laktorei u bol’nogo muzhskogo pola s transseksualizmom. / Case of galactorrhea in a transsexual male patient.] Проблемы Эндокринологии [Problemy Èndokrinologii (Moskva) / Problems of Endocrinology (Moscow)], 31(1), 37–38. [ISSN:0375-9660] [Google Scholar 1] [Google Scholar 2] [PubMed] [DOI:10.14341/probl198531137-38] [PDF] [Translation]
Kuhl, H. (1986). Hormonsubstitution durch Injektionspräparate und Hautimplantate. [Hormone substitution by injectable preparations and skin implants.] Der Gynäkologe, 19(4), 241–247. [Google Scholar] [PubMed] [PDF] [Translation]
Lauritzen, C. (27 October 1980). Hormonkur Kann Hypoplastischer Mamma Aufhelfen. [Hormone Therapy Can Help Hypoplastic Breasts.] Selecta: Medizin aktuell; das Magazin für ärztliche Fortbildung [Selecta: Medicine Currently; the Magazine for Medical Training], 22(43), 3798–3801. Planegg: Selecta-Verlag. [ISSN:0582-4877] [WorldCat] [PDF] [Translation]
Lauritzen, C. (1986). Die Behandlung der klimakterischen Beschwerden durch vaginale, rektale und transdermale Östrogensubstitution. [Treatment of disorders of the climacteric by vaginal, rectal and transdermal estrogen substitution.] Der Gynäkologe, 19(4), 248–253. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF] [Translation]
Lauritzen, C. (1988). Natürliche und synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien. [Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles.] In Lauritzen, C., Schneider, H. P. G., & Nieschlag, E. (Eds.). Grundlagen und Klinik der Menschlichen Fortpflanzung [Foundations and Clinic of Human Reproduction] (pp. 229–306). Berlin: de Gruyter. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [URL] [PDF] [Translation]
Lauritzen, C. (1989). Hormonelle Substitutionstherapie zur Brustvergrößerung. [Hormonal Substitution Therapy for Breast Enlargement.] In Beller, F. K. & Seitzer, D. (Eds.). 7. Siebte Wissenschaftliche Tagung der Deutschen Gesellschaft für Senologie, Münster, 25. - 27. September 1987: Ausgewählte Referate [7th Scientific Conference of the German Society for Senology, Münster, [Germany,] September 25–27, 1987: Selected Papers] (pp. 39–41). Mülheim, Germany: H.U.F. Verlag. [Google Scholar] [WorldCat 1] [WorldCat 2] [WorldCat 3] [Cited By 1] [Cited By 2] [Cited By 3] [PDF] [Translation]
Leyendecker, G., Geppert, G., Nocke, W., & Ufer, J. (1975). Untersuchungen zur Pharmakokinetik von Östradiol-17β, Östradiol-Benzoat, Östradiol-Valerianat und Östradiol-Undezylat bei der Frau: Der Verlauf der Konzentrationen von Östradiol-17β, Östron, LH und FSH im Serum. [Estradiol-17β, Estrone, LH and FSH in Serum After Administration of Estradiol-17β, Estradiol-Benzoate, Estradiol-Valeriate and Estradiol-Undecylate in the Female.] Geburtshilfe und Frauenheilkunde, 35(5), 370–374. [Google Scholar] [PubMed] [PDF] [Translation]
Müderris, İ. İ., & Öner, G. (2009). Hirsutizm Tedavisinde Flutamid ve Bikalutamid Kullanımı. [Flutamide and Bicalutamide Treatment in Hirsutism.] Türkiye Klinikleri Endokrinoloji-Özel Dergisi [Türkiye Klinikleri Endocrinology-Special Topics], 2(2), 110–112. [ISSN:1308-0954] [URL] [PDF] [Translation]
Müller, C. (1953). Zur Hormonalen Kosmetik der Weiblichen Brust: Wirkung und Nebenwirkung Östrogenhaltiger Kosmetischer Präparate. [Hormonal Cosmetics of the Female Breast: Effects and Side Effects of Estrogen-Containing Cosmetic Preparations.] Schweizerische Medizinische Wochenschrift [Swiss Medical Weekly], 83(4), 81–84. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF] [Translation]
Saborowski, K.-J. (1987). Konservative Therapie mit Cyproteronacetat und Estradiolundecylat beim Fortgeschrittenen Prostatacarcinom: Eine 5-Jahres-Studie. [Conservative Therapy with Cyproterone Acetate and Estradiol Undecylate in Advanced Prostate Cancer: A 5-Year Study.] (Doctoral dissertation, Ruhr-University Bochum.) [58 pages] [Google Scholar] [Google Books] [WorldCat] [PDF] [Translation]
Stege, R., Carlström, K., Hedlund, P. O., Pousette, A., von Schoultz, B., & Henriksson, P. (1995). Intramuskuläres Depotöstrogen (Estradurin®) in der Behandlung von Patienten mit Prostatakarzinom. Historische Aspekte, Wirkungsmechanismus, Resultate und aktueller klinischer Stand. [Intramuscular depot estrogens (Estradurin®) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status.] Der Urologe. Ausgabe A, 34(5), 398–403. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF] [Translation]
Stepanov, V. N., Goriunov, V. G., Chechenin, M. G., Sivkov, A. V., & Gubdurakhmanov, I. I. (1995). Ацетат Ципротерона (Авдрокур-депо) В Лечении Неоперабельного Рака Предстательной Железы. [Atsetat Tsiproterona (Androkur-Depo) V Lechenii Neoperabel’nogo Raka Predstatel’noĭ Zhelezy. / Cyproterone Acetate (Androcur-Depo) in the Treatment of Inoperable Prostatic Cancer.] Urologii︠a︡ i Nefrologii︠a︡ (Moskova), (6), 33–36. [Google Scholar] [PubMed] [PDF] [Translation]
Tønnesen, M. (1949). Om den protraherede virkning av østradiolmonobenzoat og østradioldipropionat i subcutane oliedepoter. [About the protracted effect of estradiol monobenzoate and estradiol dipropionate in subcutaneous oil depots.] Nordisk Medicin, 41(7), 324–324. [Google Scholar 1] [Google Scholar 2] [PubMed] [Google Books] [PDF] [Translation]
Tunn, U. W., Senge, T., & Jacobi, G. H. (1983). Klinische Erfahrungen mit Cyproteronacetat als Monotherapie beim Inoperablen Prostatakarzinom. [Clinical Experience with Cyproterone Acetate as a Monotherapy for Inoperable Prostate Cancer.] In Klosterhalfen, H. (Ed.). Therapie des Fortgeschrittenen Prostatakarzinoms. Vortragsveranstaltung für Urologen, Berlin 1982/83 [Therapy of Advanced Prostate Cancer. Lecture Event for Urologists, Berlin 1982/83] (Veröffentlichung der Medizinisch-Wissenschaftlichen Buchreihe von Schering, Berlin) (pp. 67–76). Berlin: Schering AG. [Google Scholar] [Google Books] [WorldCat] [PDF] [Translation]
Ushizima, Y. [牛島陽一] (1962). ホルモン剤による乳房肥大. [Enlargement of Breasts by Hormonal Therapy.] 福岡醫學雜誌 [Fukuoka Igaku Zasshi = Hukuoka Acta Medica], 53, 806–807. [Google Scholar] [PubMed] [PDF] [Translation]
Varangot, J., & Cedard, L. (1957). Modifications des Œstrogènes Sanguins Après Administration Intramusculaire de Benzoate d’Œstradiol. [Changes in Serum Estrogens After Intramuscular Administration of Estradiol Benzoate.] Comptes Rendus des Séances de la Société de Biologie et de ses Filiales, 151(10), 1707–1712. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF] [Translation]
Vizziello, G., D’Amato, G., Trentadue, R., & Fanizza, G. (1993). Studio dinamico del blocco ipofisario indotto dalla triptorelina, mediante test all’estradiolo benzoato. [Estradiol benzoate test in the study of pituitary block induced by triptorelin.] Minerva Ginecologica, 45(4), 185–189. [Google Scholar] [PubMed] [PDF] [Translation]
Wied, G. (1954). Östradiol-valerianat und Östradiol-undecylat; zwei neue protrahiert wirkende Östrogene. Wirkungsvergleich mit Östradiol-benzoat. [Estradiol valerate and estradiol undecylate, two new estrogens with prolonged action. Comparison with estradiol benzoate.] Geburtshilfe und Frauenheilkunde, 14(1), 45–52. [Google Scholar] [PubMed] [PDF] [Translation]
Zgliczynski, S., Baranowska, B., & Szymanowski, J. (1981). L’influence du spironolactone sur la concentration des gonatrophines et des hormones gonadiques dans l’hypertrophie prostatique. [The influence of spironolactone on the concentration of gonadotrophins and gonadal hormones in prostatic hypertrophy]. Journal d’Urologie, 87(9), 635–638. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF] [Translation]